Absorption Systems has secured US patent number 7,795,019, from the US Patent and Trademark Office (USPTO), covering its breast cancer resistance protein (BCRP) knockdown cell line within the company’s CellPort Technologies brand.

CellPort Technologies is a suite of in-vitro test systems designed to provide definitive data regarding interactions between drugs and specific transporter proteins like BCRP.

BCRP is a key mediator of unintended drug interactions as identified by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

The patent assigned to Absorption Systems is titled as ‘Stable Cell Lines and Methods for Evaluating Gastrointestinal Absorption of Chemicals.’

Absorption Systems president and CEO Patrick Dentinger said that this patent further confirms the uniqueness of the approach that the companyhas taken and they believe that using CellPort Technologies gives pharmaceutical and biotech companies a significant advantage by providing the information required by the FDA.